ERBB2 and cancer: Novel anti-HER2 ADCs with structural innovations are being developed [37,45], and combinations of anti-HER2 ADCs with other types of anti-cancer agents such as immune checkpoint inhibitors, tyrosine kinase inhibitors, or CDK4/6 inhibitors are also being investigated [37,46].